Tech Company Inital Public Offerings

Inotek Pharmaceuticals IPO

On 2/19/2015, Inotek Pharmaceuticals went public.

Transaction Overview

Announced On
2/19/2015
Transaction Type
IPO
Amount
$40,200,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1202 Water St.
Walnut Creek, CA 94597
USA
Email Address
Overview
Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.
Profile
Inotek Pharmaceuticals LinkedIn Company Profile
Social Media
Inotek Pharmaceuticals Company Twitter Account
Company News
Inotek Pharmaceuticals News
Facebook
Inotek Pharmaceuticals on Facebook
YouTube
Inotek Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Southwell
  David Southwell LinkedIn Profile  David Southwell Twitter Account  David Southwell News  David Southwell on Facebook
Chief Medical Officer
Rudolf Baumgartner
  Rudolf Baumgartner LinkedIn Profile  Rudolf Baumgartner Twitter Account  Rudolf Baumgartner News  Rudolf Baumgartner on Facebook
Chief Scientific Officer
William McVicar
  William McVicar LinkedIn Profile  William McVicar Twitter Account  William McVicar News  William McVicar on Facebook
VP - Finance
Dale Ritter
  Dale Ritter LinkedIn Profile  Dale Ritter Twitter Account  Dale Ritter News  Dale Ritter on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/19/2015: Vennli venture capital transaction
Next: 2/19/2015: Livefyre venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary